COVID-19 vaccine tracker

Posted 18 February 2021 | By Jeff Craven

The worldwide endeavor to create a safe and effective COVID-19 vaccine is

bearing fruit. Almost a dozen vaccines now have been authorized around the
globe; many more remain in development.

To clarify the landscape for our readers, our vaccine tracker has been split in
two. The first chart details vaccines that have achieved regulatory
authorization or approval; the second continues to follow candidates in
Phase 1-3 clinical trials and some promising candidates in early
development. To reveal in-depth information about each candidate, select
the “Details” button above the chart or click on the green plus button next to
each entry.

Information about the unprecedented public/private partnerships spawned by

the COVID-19 public health emergency now can be found below the charts.

Our charts will be updated weekly. If you wish to submit an update or notice
an issue with this data, please email Focus at news@raps.org.

Updated 18 February to include the first authorization of Johnson &

Johnson’s JNJ-78436735 as well as new information on authorized/approved
vaccines from Pfizer/BioNTech, Moderna, AstraZeneca, Gamaleya Research Institute, Sinovac, SinoPharm, and CanSino Biologics as well as new information on
vaccine candidates from CureVac, Zydus Cadila, UKE-Hamburg, Altimmune, and Sanofi.

Authorized/approved vaccines

SHOW/HIDE DETAILS

Show entries
Search:
 Country
Name Vaccine Type Primary Developers Authorization/Approval
of Origin

Albania, Argentina, Australia, Bahrain, Canada, Chile, Colombia,

Costa Rica, Ecuador, EU, Faroe Islands, Greenland, Iceland, Iraq,
Comirnaty mRNA-based Israel, Japan, Jordan, Kuwait, Malaysia, Mexico, New Zealand,
Pfizer, BioNTech; Fosun Pharma Multinational
(BNT162b2) vaccine Norway, Oman, Panama, Philippines, Qatar, Saint Vincent and the
Grenadines, Saudi Arabia, Serbia, Singapore, Switzerland, UAE,
UK, US, Vatican City, WHO

Moderna COVID-19 Canada, EU, Faroe Islands, Greenland, Iceland, Israel, Norway,
mRNA-based
Vaccine (mRNA- Moderna, BARDA, NIAID US Qatar, Saint Vincent and the Grenadines, Singapore, Switzerland,
vaccine
1273) United Kingdom, United States

Argentina, Bahrain, Bangladesh, Brazil, Chile, Dominican Republic,

COVID-19 Vaccine
Ecuador, El Salvador, EU, Hungary, India, Iraq, Mexico, Morocco,
AstraZeneca Adenovirus
BARDA, OWS UK Myanmar, Nepal, Pakistan, Philippines, Saint Vincent and the
(AZD1222); also vaccine
Grenadines, South Africa, South Korea, Sri Lanka, Thailand, UK,
known as Covishield
Vietnam

Algeria, Argentina, Armenia, Bahrain, Belarus, Bolivia, Gabon,

Guinea, Hungary, Iran, Kazakhstan, Laos, Lebanon, Mexico,
Gamaleya Research Institute,
Non-replicating Mongolia, Montenegro, Myanmar, Nicaragua, Pakistan, Palestine,
Sputnik V Acellena Contract Drug Research Russia
viral vector Paraguay, Republika Srpska, Russia, Saint Vincent and the
and Development
Grenadines, Serbia, Tunisia, Turkmenistan, United Arab Emirates,
Uzbekistan, Venezuela

Inactivated
vaccine (formalin Azerbaijan, Bolivia, Brazil, Cambodia, China, Chile, Colombia,
CoronaVac Sinovac China
with alum Indonesia, Laos, Turkey, Uruguay
adjuvant)

Beijing Institute of Biological

Inactivated Products; China National Bahrain, Cambodia, China, Egypt, Hungary, Iraq, Jordan, Laos,
BBIBP-CorV China
vaccine Pharmaceutical Group Macau, Morocco, Pakistan, Peru, Serbia, Seychelles, UAE
(Sinopharm)

Federal Budgetary Research

EpiVacCorona Peptide vaccine Institution State Research Center Russia Russia, Turkmenistan
of Virology and Biotechnology
 Country
Name Vaccine Type Primary Developers Authorization/Approval
of Origin

Recombinant
Convidicea (Ad5- vaccine
CanSino Biologics China Mexico, China (military use), Pakistan
nCoV) (adenovirus type
5 vector)

Inactivated
Covaxin Bharat Biotech, ICMR India India
vaccine

Wuhan Institute of Biological

Inactivated Products; China National
No name announced China China
vaccine Pharmaceutical Group
(Sinopharm)

JNJ-78436735 The
Non-replicating Janssen Vaccines (Johnson &
(formerly Netherlands, Saint Vincent and the Grenadines
viral vector Johnson)
Ad26.COV2.S) US

Showing 1 to 11 of 11 entries
Previous1Next

Vaccine candidates in development

SHOW/HIDE DETAILS

Show entries
Search:

Trial
Candidate Mechanism Sponsor Institution
Phase

NVX-CoV2373 Nanoparticle vaccine Novavax Phase 3 Novavax

Anhui Zhifei Longcom Biopharmaceutical, Institute of

ZF2001 Recombinant vaccine Phase 3 Various
Microbiology of the Chinese Academy of Sciences

ZyCoV-D DNA vaccine (plasmid) Zydus Cadila Phase 3 Zydus Cadila

 Trial
Candidate Mechanism Sponsor Institution
Phase

CVnCoV mRNA-based vaccine CureVac; GSK Phase 2b/3 CureVac

University of Melbourne and Murdoch Children’s University of Melbourne and Murdoch

Bacillus
Research Institute; Radboud University Medical Children’s Research Institute; Radboud
Calmette-Guerin Live-attenuated vaccine Phase 2/3
Center; Faustman Lab at Massachusetts General University Medical Center; Faustman
(BCG) vaccine
Hospital Lab at Massachusetts General Hospital

Center for Pharmaceutical Research,

INO-4800 DNA vaccine (plasmid) Inovio Pharmaceuticals Phase 2/3 Kansas City. Mo.; University of
Pennsylvania, Philadelphia

VIR-7831 Plant-based adjuvant vaccine Medicago; GSK; Dynavax Phase 2/3 Medicago

No name
Adenovirus-based vaccine ImmunityBio; NantKwest Phase 2/3
announced

Multitope peptide-based
UB-612 COVAXX Phase 2/3 United Biomedical Inc. (UBI)
vaccine

Abdala (CIGB
Protein subunit vaccine Finlay Institute of Vaccines Phase 2 Finlay Institute of Vaccines
66)

Phase Multiple study sites in Europe, North

BNT162 mRNA-based vaccine Pfizer, BioNTech
1/2/3 America and China

AdCLD-CoV19 Adenovirus-based vaccine Cellid; LG Chem Phase 1/2a Korea University Guro Hospital

Recombinant vaccine (Spike

Nanocovax Nanogen Biopharmaceutical Phase 1/2 Military Medical Academy (Vietnam)
protein)

EuCorVac-19 nanoparticle vaccine EuBiologics Phase 1/2 Eunpyeong St. Mary’s Hospital

Mambisa (CIGB
Protein subunit vaccine Finlay Institute of Vaccines Phase 1/2 Finlay Institute of Vaccines
669)

Recombinant vesicular
Hadassah Medical Center; Sheba
IIBR-100 stomatitis virus (rVSV) Israel Institute for Biological Research Phase 1/2
Medical Center Hospital
vaccine
 Trial
Candidate Mechanism Sponsor Institution
Phase

No name
SF9 cell vaccine candidate West China Hospital, Sichuan University Phase 1/2 West China Hospital, Sichuan University
announced

Soberana 1 and 2 Monovalent/conjugate vaccine Finlay Institute of Vaccines Phase 1/2 Finlay Institute of Vaccines

VLA2001 Inactivated vaccine Valneva; National Institute for Health Research (NIHR) Phase 1/2 Multiple NIHR testing sites

No name Adjuvanted protein subunit

CEPI Phase 1/2
announced vaccine

AG0301- AnGes, Inc.; Japan Agency for Medical

DNA vaccine AnGes, Inc. Phase 1/2
COVID19 Research and Development

GX-19N DNA vaccine Genexine Phase 1/2

ARCT-021
(LUNAR- Self-replicating RNA vaccine Arcturus Therapeutics and Duke-NUS Medical School Phase 1/2 Duke-NUS Medical School, Singapore
COV19)

No name
Protein subunit vaccine Sanofi; GlaxoSmithKline Phase 1/2 Various
announced

West China Second University Hospital,

No name Chinese Academy of Medical Sciences, Institute of
Inactivated vaccine Phase 1/2 Yunnan Center for Disease Control and
announced Medical Biology
Prevention

University of Washington; National Institutes of Health

HDT-301
RNA vaccine Rocky Mountain Laboratories; HDT Bio Phase 1/2
(HGCO19)
Corp; Gennova Biopharmaceuticals

AV-COVID-19 Dendritic cell vaccine Aivita Biomedical, Inc. Phase 1b/2 Rumah Sakit Umum Pusat Dr Kariadi

PTX-COVID19-
mRNA-based vaccine Providence Therapeutics; Canadian government Phase 1
B

COVI-VAC Intranasal vaccine Codagenix; Serum Institute of India Phase 1

CORVax12 DNA vaccine (plasmid) OncoSec; Providence Cancer Institute Phase 1 Providence Portland Medical Center
 Trial
Candidate Mechanism Sponsor Institution
Phase

Universitätsklinikum Hamburg-Eppendorf; German

Modified vaccinia virus
Center for Infection Research; Philipps University University Medical Center Hamburg-
MVA-SARS-2-S ankara (MVA) vector vaccine Phase 1
Marburg Medical Center; Ludwig-Maximilians - Eppendorf
candidate
University of Munich

Modified vaccinia virus

COH04S1 ankara (MVA) vector vaccine City of Hope Medical Center; National Cancer Institute Phase 1 City of Hope Medical Center
candidate

Multi-peptide vaccine
pVAC University Hospital Tuebingen Phase 1 University Hospital Tuebingen
candidate

AdimrSC-2f Protein subunit vaccine Adimmune Phase 1 Adimmune

Monovalent oral vaccine

bacTRL-Spike Symvivo Phase 1 Symvivo Corporation
(bifidobacteria)

Monovalent recombinant
COVAX-19 Vaxine Pty Ltd. Phase 1 Royal Adelaide Hospital
protein vaccine

DelNS1-2019-
Xiamen University, Beijing Wantai Biological Jiangsu Provincial Centre For Disease
nCoV-RBD- Replicating viral vector Phase 1
Pharmacy Control and Prevention
OPT1

Lazzaro Spallanzani National Institute

GRAd-COV2 Adenovirus-based vaccine ReiThera; Leukocare; Univercells Phase 1
for Infectious Diseases

UQ-CSL V451 Protein subunit vaccine CSL; The University of Queensland Phase 1

GlaxoSmithKline, Sanofi, Clover

SCB-2019 Protein subunit vaccine Biopharmaceuticals, Dynavax and Xiamen Innovax; Phase 1 Linear Clinical Research (Australia)
CEPI

Recombinant vaccine
VXA-CoV2-1 Vaxart Phase 1 Vaxart
(adenovirus type 5 vector)

AdCOVID Intranasal vaccine Altimmune Phase 1 University of Alabama at Birmingham

 Trial
Candidate Mechanism Sponsor Institution
Phase

Massachusetts Eye and Ear; Massachusetts General

AAVCOVID Gene-based vaccine Pre-clinical
Hospital; University of Pennsylvania

ChAd-SARS- Washington University School of

Adenovirus-based vaccine Washington University School of Medicine in St. Louis Pre-clinical
CoV-2-S Medicine in St. Louis

MGH Vaccine and Immunotherapy

HaloVax Self-assembling vaccine Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc. Pre-clinical
Center

LineaDNA DNA vaccine Takis Biotech Pre-clinical Takis Biotech

MRT5500 mRNA-based vaccine Sanofi, Translate Bio Pre-clinical

No name Ii-Key peptide COVID-19

Generex Biotechnology Pre-clinical Generex
announced vaccine

University of Saskatchewan Vaccine and

No name University of Saskatchewan Vaccine and Infectious
Protein subunit vaccine Pre-clinical Infectious Disease Organization-
announced Disease Organization-International Vaccine Centre
International Vaccine Centre

No name Chulalongkorn University’s Center of Excellence in

mRNA-based vaccine Pre-clinical
announced Vaccine Research and Development

No name University of Miami Miller School of

gp96-based vaccine Heat Biologics Pre-clinical
announced Medicine

No name
Inactivated vaccine Shenzhen Kangtai Biological Products Pre-clinical
announced

Recombinant protein subunit

PittCoVacc vaccine (delivered through UPMC/University of Pittsburgh School of Medicine Pre-clinical University of Pittsburgh
microneedle array)

T-COVIDTM Intranasal vaccine Altimmune Pre-clinical

No longer
LNP-
Self-amplifying RNA vaccine Imperial College London being Imperial College London
nCoVsaRNA
studied
 Trial
Candidate Mechanism Sponsor Institution
Phase

No longer
Recombinant vaccine
V590 Merck; IAVI being
(vesicular stomatitis virus)
studied

No longer
University of Pittsburgh; Themis
V591 Measles vector vaccine University of Pittsburgh’s Center for Vaccine Research being
Biosciences; Institut Pasteur"
studied

Showing 1 to 57 of 57 entries
Previous1Next

COVID-19 vaccine initiatives

OWS: Operation Warp Speed is a collaboration of several US government departments including Health and Human Services (HHS) and subagencies, Defense,
Agriculture, Energy and Veterans Affairs and the private sector. OWS has funded JNJ-78436735 (Janssen), mRNA-1273 (Moderna), and NVX-CoV2373
(Novavax), V590 (Merck/IAVI), V591 (Merck/Themis), AZD1222 (AstraZeneca/University of Oxford), and the candidate developed by Sanofi and GlaxoSmithKline.

OWS is “part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.” Leaders
of OWS say they could vaccinate as many as 20 million people by the end of the year and 100 million people by February.

ACTIV: Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18 biopharmaceutical companies in an initiative called ACTIV. ACTIV
aims to fast-track development of drug and vaccine candidates for COVID-19.

COVPN: The COVID-19 Prevention Trials Network (COVPN) combines clinical trial networks funded by the National Institute of Allergy and Infectious Diseases
(NIAID): the HIV Vaccine Trials Network (HVTN), HIV Prevention Trials Network (HPTN), Infectious Diseases Clinical Research Consortium (IDCRC), and the
AIDS Clinical Trials Group.

COVAX: The COVAX initiative, part of the World Health Organization’s (WHO) Access to COVID-19 Tools (ACT) Accelerator, is being spearheaded by the
Coalition for Epidemic Preparedness Innovations (CEPI); Gavi, the Vaccine Alliance; and WHO. The goal is to work with vaccine manufacturers to offer low-cost
COVID-19 vaccines to countries. CEPI’s candidates from companies Inovio, Moderna, CureVac, Institut Pasteur/Merck/Themis, AstraZeneca/University of Oxford,
Novavax, University of Hong Kong, Clover Biopharmaceuticals, and University of Queensland/CSL are part of the COVAX initiative. The US joined COVAX on 21
January. The most up-to-date forecast of COVAX's vaccine supply can be found here.